As a TNF inhibitor, Infliximab (IFX) was first used for the treatment of refractory uveitis in BD over 20 years ago (9), and is currently the most frequently administered agent for BD-associated uveitis in Japan. This evidence concerns the gene TNF and Behcet disease.